Alnylam Pharmaceuticals Inc (ALNY)
NASDAQ
News
Market Data
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ALNY market cap is 31.2B. The company's latest EPS is USD -2.1486 and P/E is -112.25.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 439.72M | 494.33M | 659.83M | 500.92M | 593.17M |
| Operating Income | -116.4M | -43.44M | 48.61M | -76.91M | -105.16M |
| Net Income | -137.87M | -65.94M | -16.89M | -111.57M | -83.76M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 492.85M | 844.29M | 1.04B | 1.83B | 2.25B |
| Operating Income | -828.44M | -708.65M | -785.07M | -282.18M | -176.89M |
| Net Income | -858.28M | -852.82M | -1.13B | -440.24M | -278.16M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 3.83B | 3.82B | 4.01B | 4.21B | 4.24B |
| Total Liabilities | 4.05B | 4.04B | 4.01B | 4.17B | 4.17B |
| Total Equity | -220.64M | -219.27M | -3.07M | 32.35M | 67.09M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 3.41B | 3.64B | 3.55B | 3.83B | 4.24B |
| Total Liabilities | 2.39B | 3.06B | 3.7B | 4.05B | 4.17B |
| Total Equity | 1.02B | 588.2M | -158.22M | -220.64M | 67.09M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 104.16M | -81.52M | 42.64M | 86.35M | -8.31M |
| Investing | -336.35M | -67.62M | -33.68M | -63.93M | -116.84M |
| Financing | 172.13M | 28.91M | 160.41M | 263.16M | 294.16M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -614.96M | -641.69M | -541.27M | 104.16M | -8.31M |
| Investing | -435.52M | -273.3M | 169.35M | -336.35M | -116.84M |
| Financing | 994.98M | 1.25B | 425.75M | 172.13M | 294.16M |
| Market Cap | 31.2B |
| Price to Earnings Ratio | -112.25 |
| Price to Sales Ratio | 13.89 |
| Price to Cash Ratio | 32.31 |
| Price to Book Ratio | 465.38 |
| Dividend Yield | - |
| Shares Outstanding | 129.46M |
| Average Volume (1 week) | 1.02M |
| Average Volume (1 Month) | 779.75k |
| 52 Week Change | 57.35% |
| 52 Week High | 304.39 |
| 52 Week Low | 141.975 |
| Spread (Intraday) | 0.43 (0.18%) |
| Company Name | Alnylam Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.alnylam.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
